Pancreatic Cancer Pill Shows New Early-Stage Results: What Canadians Should Know

Verified and updated: November 20, 2026, 20:01 UTC.

A new update presented today at the EORTC-NCI-AACR cancer symposium in Barcelona reports that daraxonrasib, an oral cancer drug, combined with chemotherapy was associated with tumour shrinkage in about six in 10 people with metastatic pancreatic cancer. The phase I/II study included just 61 patients, and it did not compare the combination with chemotherapy alone. The result is an encouraging early signal, not proof that the combination extends survival.

The update is distinct from earlier phase III findings for daraxonrasib after prior treatment: the new report examines its use alongside chemotherapy as an initial treatment for metastatic disease. For Canadians, the research is not itself a treatment approval or a guarantee that the drug is available through routine care.

Highlights

  • In a 61-patient early-phase study, tumours shrank or became undetectable in 60.7% of participants.
  • Complete responses, where tumours were no longer detectable, were reported in 8.2%; disease control was 90.2%.
  • Median progression-free survival was 12.8 months, but there was no randomized chemotherapy-only comparison.
  • A global phase III trial is testing whether the approach improves outcomes; the FDA has separately approved daraxonrasib for certain U.S. patients, while this study does not establish Canadian access.

What did the latest pancreatic cancer pill trial find?

According to the symposium’s report on the RMC-GI-102 study, 61 patients had received daraxonrasib with gemcitabine and nab-paclitaxel by September 28. After a median follow-up of 18.3 months, investigators reported an objective response rate of 60.7%. That measure counts tumours that shrank substantially or disappeared on assessment. Complete responses were reported in 8.2% of participants, while 90.2% had disease control, meaning their cancer shrank or did not grow during the measured period.

Median progression-free survival—the time until cancer worsened or death—was 12.8 months. The report also gave a 12-month overall survival estimate of 76.6%. These numbers describe outcomes in this group; without a randomized control group, they cannot show how much of the result came from the pill rather than chemotherapy, patient selection, or other factors. The trial was sponsored by Revolution Medicines, the drug’s developer. Read the EORTC-NCI-AACR symposium’s study update.

How is daraxonrasib being tested with chemotherapy?

Daraxonrasib is designed to interfere with active RAS signalling, a pathway that drives the growth of many pancreatic cancers. In the reported regimen, patients took the pill once daily and also received gemcitabine and nab-paclitaxel by intravenous infusion on days 1 and 15 of each treatment cycle. So, despite the “pill” shorthand, this combination still includes chemotherapy infusions.

The most commonly reported side effects included rash, diarrhoea and fatigue, alongside effects associated with chemotherapy, such as low blood-cell counts. The symposium report said treatment discontinuation because of daraxonrasib-related side effects occurred in 5% of participants. A small early-phase study cannot fully characterize uncommon or longer-term risks.

How do the new results compare with the phase III findings?

In a separate randomized phase III trial, RASolute 302, 500 people whose metastatic pancreatic cancer had progressed after one prior line of treatment received daraxonrasib or a doctor-selected chemotherapy. The U.S. Food and Drug Administration reported median overall survival of 13.2 months with daraxonrasib and 6.7 months with chemotherapy in the overall study population. Median progression-free survival was 7.2 versus 3.6 months. That is stronger comparative evidence for the studied later-line setting; it does not establish the benefit of adding the pill to chemotherapy as first-line treatment.

On August 26, the FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. The FDA says it collaborated with Health Canada during the review, but the U.S. approval notice is not a Canadian authorization. The latest early-phase results also do not expand the approved use. See the FDA approval and trial data.

What happens next, and what does this mean in Canada?

The key next step is a larger randomized study. The global phase III RASolute-303 trial is evaluating daraxonrasib alone and with gemcitabine plus nab-paclitaxel against chemotherapy in previously untreated metastatic pancreatic cancer. That comparison can help determine whether the early response and disease-control signals translate into better outcomes.

For people in Canada, the symposium announcement does not mean the drug is routinely available or funded here. FDA authorization applies in the United States; Canadians should ask their oncology team about relevant clinical trials, regulatory status and possible access routes. Trial eligibility varies, and treatment decisions depend on an individual’s diagnosis and medical history.

Dana-Farber’s trial summary describes the phase III study and the drug’s RAS-targeting approach.

Frequently asked questions

Is daraxonrasib a cure for pancreatic cancer?

No. The available studies report tumour response and survival outcomes in advanced disease; they do not show a cure.

Does the new combination mean patients can stop chemotherapy?

No. In the phase I/II study, daraxonrasib was given alongside two intravenous chemotherapy drugs.

Can Canadians get daraxonrasib now?

The new trial results do not establish routine Canadian access. Ask an oncologist about current Canadian regulatory status and clinical-trial options.

Leave a Comment

GTA 6 Gameplay and Features: What’s Confirmed as of November 21, 2026

GTA 6 Gameplay and Features: What’s Confirmed as of November 21, 2026

See what Rockstar has confirmed about GTA 6 gameplay, Jason and Lucia, Leonida’s locations, platforms, visuals, and features—and what remains undisclosed.

How to Protect Your Superannuation From AI Phone Scams | November 21, 2026

How to Protect Your Superannuation From AI Phone Scams | November 21, 2026

An AI-generated call about superannuation highlights risks from cold callers and scams. Learn how to verify callers, protect account details, and act if you shared information.

GTA VI Is Out Now: Platforms, Story and What Comes Next — 20 November 2026

GTA VI launched on PS5 and Xbox Series X|S on 19 November. Here is what Australian players need to know about availability, the story, PC status and next steps.

Ellen Fanning’s AI Superannuation Call: What Australians Need to Know on November 20

An AI caller targeting Ellen Fanning’s super details has been reported across Australia. Here’s what the latest reporting and official guidance say to do.

How AI Voice Calls Could Put Australian Super at Risk

An AI caller named Alex has cold-called Australians about switching super funds. Learn how lead generation works and how to protect your retirement savings.

UK Emergency Preparedness: Household Essentials You Actually Need | November 20, 2026

UK Emergency Preparedness: Household Essentials You Actually Need | November 20, 2026

Build a practical three-day UK emergency kit with water, no-cook food, light, medicines, and a plan—without panic buying or waste.

Billie Eilish Confirmed for BST Hyde Park 2027: July 3 Date and Ticket Prices

Billie Eilish is confirmed for BST Hyde Park on July 3, 2027. See current ticket prices, presale and general sale dates, and what is still to be announced.

BST Hyde Park 2027: Headliners, Tickets and Confirmed Dates

Bon Jovi, Muse, Billie Eilish and RAYE are among BST Hyde Park 2027’s confirmed headliners. See dates, ticket prices, sale details and what is still to come.

UK Emergency Stockpiling: Essential Grocery Sales Jump After Be Ready Advice | Nov. 20, 2026

UK Emergency Stockpiling: Essential Grocery Sales Jump After Be Ready Advice | Nov. 20, 2026

UK emergency-preparedness purchases rose after Be Ready advice. See the latest grocery sales data, what it measures, and what the government actually recommends.

Why UK Shoppers Are Stocking Up on Groceries: What the Latest Data Shows (November 20, 2026)

UK food-store sales rose in October as shoppers bought more long-life groceries after the Be Ready campaign. Here’s what the data and official advice mean.